Director Clinical Pharmacology
SK Life Science
Director Clinical Pharmacology
SK Life Science
Develops CNS and cancer therapies
The Clinical Pharmacology (CP) Director role will effectively provide expertise and support for the design, execution, interpretation and reporting of clinical pharmacokinetic/pharmacodynamic (PK/PD) studies. This individual will participate in the selection of Phase 1 CROs for clinical pharmacology studies. Individual will be functional CP Lead will ensure that the preclinical characterization is adequate and provides support in characterizing the clinical pharmacology profile of a given compound; and also ensure that the CP strategy/plans fully support the selection of dose(s) and regimen for Phase 1, 2 and 3 studies. Individual will serve as CP representative on studies and project teams, and will contribute to the planning, writing, implementation and organization of regulatory filings along with presentation of PK/PD data to internal cross-functional teams and external collaborators. This individual may provide oversight and be responsible for the pharmacometric related analyses and activities in support of the CP profile of a compound and may also serve as a mentor to less experienced staff and as a Clinical Pharmacology resource within the function and across the company eg in matters related to due diligence.
Compensation & Benefits
The anticipated salary range for this position is $150,000 to $220,000. Actual compensation may vary based on factors including experience, qualifications, skills, and business needs.
In addition to base salary, SK Life Science offers a competitive benefits package, including a 401(k) plan with company match and medical, dental, and vision coverage. Benefits are subject to eligibility requirements and may be modified at the Company's discretion.
Develops CNS and cancer therapies
SK Life Science is a U.S. subsidiary focused on developing medicines for central nervous system (CNS) disorders and cancer. Its work centers on researching and bringing pharmaceutical treatments to market that address neurological diseases and oncology, leveraging the broader SK Group’s resources and expertise. The company’s products work by targeting disease mechanisms in CNS conditions or cancer, delivered through conventional pharmaceutical formulations developed through its science-driven pipeline (as part of SK Biopharmaceuticals). What sets SK Life Science apart from competitors is its backing by SK Group and SK Biopharmaceuticals, enabling strong research, development, and global scale, as well as a stated commitment to real patient impact in CNS and oncology. The company aims to transform lives by delivering meaningful treatments that improve outcomes for patients with CNS disorders and cancer.
Explore more opportunities at SK Life Science